Distinguish and deliver your brand’s total value proposition around the globe.
When launching products outside the U.S., Xcenda provides deep understanding of the environment, competition, and considerations for market access across Europe and HTA countries. We evaluate how your product many be viewed by payers and assess what may be needed beyond your clinical trials. We can help you engage early with key decision-makers and provide timely advice on strategy and execution.
|
Generate RWE for 18/20 pharma manufacturers |
Drive 50% of all AMNOG submissions |
Develop more than 15 Global Value Dossiers annually |
|---|---|---|
| > 700 RWE projects across 6 countries | HEOR experts and ex-payers from 22 countries | Created GVD development process shared among biopharma manufacturers |
| 180+ SLRs/NMAs | Market leaders in support submission process | 530 HTA submissions in 13 countries |
| 800+ models | Market access support through GBA and evidence package | Trusted experience in gaining alignment between global and local affiliates |
Our robust consulting partnership extends your reach on the local level.
- Global market access consulting
- Local market access consulting
- Global payer insights
- Early HTA consultation & scientific advice
- Flexible economic models
- Epidemiology assessments
- Global value dossiers
- Pricing research
- Retrospective (database) studies
- Global HTA/Reimbursement assessment
- Global advisory boards
eBook
Strategic partnerships for unlocking product potential
Ensure payer insights are obtained during product development
Value identification process
Develop your product's most effective value story
Identify the evidence that reveals your value
Access global solutions for local launch success
Real-world evidence on a global level
With strategic global data partnerships in the US, Germany, the UK, the Netherlands, France, Sweden, Canada, Japan, and China, we support our clients' global strategies along the entire product lifecycle.
Our databases are sourced from administrative claims, electronic medical records, or disease registries, and capture patient-level health information and outcomes for healthcare services performed in various care settings. Furthermore, our consultants have applied experience in designing customized prospective studies and primary data collections, including the initiation of specific cancer registries. With over 20 years of experience utilizing real-world data, we are well equipped to leverage these data sources and design tailored studies that measure and demonstrate product value in global markets.
Partnering with us allows our manufacturing partners to:- Define their market potential
- Measure medication adherence/compliance and quality metrics
- Assess resource utilization and cost of care from various perspectives
- Maximize study sample size and power
- Identify relevant clinical comparators clinical trials
- Understand current gaps in care
- Capture patient and provider perspective and the impact of settings of care on study measures and outcomes
Market research
Ask local experts from markets worldwide
Global market access network
HTA Quarterly | Summer 2020
The era of mHealth: A global perspective
